Calcium & Bone Health Institute
CBHI is a scientific, research-based non-profit institute that was founded in 2011.
The primary focus of the research is to unveil the diverse roles of calcium in the human body. We collaborate with numerous leaders and researchers from different disciplines to understand the complexity and integrity of the biological and physiological characteristics and interactions of calcium.
Our Research Philosophy
CBHI approaches disease treatment through a fundamental biological principle: the Bone Serum Ionized Ca/P/Mg Homeostasis Disease Axis. In essence, many chronic diseases originate from a disruption of blood mineral homeostasis, particularly ionized calcium, phosphorus, and magnesium, driven by prolonged calcium deficiency and sustained osteoclast activation. When this mineral imbalance persists, systemic signaling pathways governing metabolism, immunity, and tissue integrity become progressively dysregulated. Treatments that target only downstream symptoms without restoring this foundational mineral homeostasis may offer short-term relief, but they fail to correct the underlying cause and can ultimately contribute to disease chronicity. For this reason, CBHI is committed to therapeutic strategies that restore physiological mineral balance, aiming not only to treat disease, but to prevent its progression and promote true biological recovery.
Within this framework, SAC calcium is investigated as a physiological reset mechanism. By normalizing chronic osteoclast hyperactivity and restoring blood Ca/P/Mg ionic homeostasis, it helps return degenerative conditions, including cancer and neurodegenerative diseases, to a physiological state in which therapeutic interventions may regain effectiveness.
Collaborative Research Network
The extensive research team includes top-notch research organizations such as UAMS, Moffitt Cancer Center USF, Sungkyunkwan University, and other affiliated institutions. This collaboration allows us to combine our research with fundamental sciences such as Chemistry, Cell Biology, Oncology, and Osteology. The research areas are further extended through the incorporation of applied sciences such as Engineering and Computing Science to bring significant improvements in the calcium-focused research advancements.
CBHI Canada and Its Research Focus
Calcium & Bone Health Institute of Canada (CBHI) stands out among the few research-based institutes in the country wherein studies are conducted about calcium-related chronic diseases including osteoporosis and cancer. CBHI Canada strives to offer high-quality care for patients through the development and implementation of innovative and effective prevention and treatment methods as an attempt to contribute to the alleviation of the global costs of calcium-related diseases.
Research Outcomes and Clinical Impact
Building upon this physiological framework, CBHI has conducted extensive laboratory and clinical investigations using SAC as a translational research platform. For the achievement of our goal, we have proved the efficacy of Sigma Anti-Bonding Calcium Carbonate (CaCO₃) in treating calcium-related diseases by conducting laboratory and clinical research with other partners around the globe. We are making consistent endeavors to prevent the progression of osteoporosis. Since 2011, we have been triumphant in the provision of comprehensive osteoporosis treatment using SAC products. Consequently, more than 300,000 people worldwide have experienced the efficacy of SAC.
Location and Institutional Support
The CBHI is located in Coquitlam, B.C. (Canada) with full sponsorship from Marahdeo Holdings, Marah Natural, Pronuvia, and NTS Research. Each organization has a distinctive specialized research agenda, unique objectives, and pioneering achievements in the calcium-focused industry. This liaison has allowed us to remain committed towards the integration of our innovative expertise for discovering the cause and cure for calcium-related diseases.
